Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immuneering Corp. Class A (IMRX)
:IMRX
IMRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.00 - $7.68
Previous CloseN/A
Volume3.55M
Average Volume (3M)3.35M
Market Cap
$57.13M
Enterprise Value$27.89M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Mar 05, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding31,050,447
10 Day Avg. Volume323,555
30 Day Avg. Volume3,347,759
Standard Deviation0.41
R-Squared0.00186
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2975.67
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-36.50
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$10.00Price Target Upside464.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical DataInitial Phase 2a efficacy data from IMM-1-104 in combination with chemotherapy shows a promising overall response rate of 40% and a disease control rate of 80%.
InvestmentManagement has raised approximately $14M in net proceeds, supporting further development based on the data update.
PartnershipsPartnering with a global pharmaceutical company like Regeneron provides external validation of Immuneering's technology.
Bears Say
Market FocusInvestors are likely to focus on durability of response and duration of treatment as potential signals for Phase 3.
Stock PerformanceDespite the positive data, the stock has surprisingly declined since the announcement.
---
Ownership Overview
30.64% Insiders
6.06% Mutual Funds
1.23% Other Institutional Investors
58.47% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMRX FAQ
What was Immuneering Corp. Class A’s price range in the past 12 months?
Immuneering Corp. Class A lowest stock price was $1.00 and its highest was $7.68 in the past 12 months.
What is Immuneering Corp. Class A’s market cap?
Immuneering Corp. Class A’s market cap is $57.13M.
When is Immuneering Corp. Class A’s upcoming earnings report date?
Immuneering Corp. Class A’s upcoming earnings report date is Mar 05, 2025 which is in 12 days.
How were Immuneering Corp. Class A’s earnings last quarter?
Immuneering Corp. Class A released its earnings results on Nov 13, 2024. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.552 by $0.062.
Is Immuneering Corp. Class A overvalued?
According to Wall Street analysts Immuneering Corp. Class A’s price is currently Undervalued.
Does Immuneering Corp. Class A pay dividends?
Immuneering Corp. Class A does not currently pay dividends.
What is Immuneering Corp. Class A’s EPS estimate?
Immuneering Corp. Class A’s EPS estimate is -0.45.
How many shares outstanding does Immuneering Corp. Class A have?
Immuneering Corp. Class A has 31,050,447 shares outstanding.
What happened to Immuneering Corp. Class A’s price movement after its last earnings report?
Immuneering Corp. Class A reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.552. Following the earnings report the stock price went up 13.45%.
Which hedge fund is a major shareholder of Immuneering Corp. Class A?
Among the largest hedge funds holding Immuneering Corp. Class A’s share is Perceptive Advisors LLC. It holds Immuneering Corp. Class A’s shares valued at 0.
---
Immuneering Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (464.97% Upside)
$10.00 (464.97% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-73.18%
12-Months-Change
Fundamentals
Return on Equity
-71.81%
Trailing 12-Months
Asset Growth
-39.80%
Trailing 12-Months
Company Description
Immuneering Corp. Class A
Immuneering Corpbiopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
---
IMRX Stock 12 Month Forecast
Average Price Target
$10.00
▲(464.97% Upside)
Technical Analysis
Best Analysts Covering IMRX
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-13.03%
reiterated a buy rating 5 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -13.03% per trade.
---